Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as NC-503 (eprodisate disodium)
NC-503 · 2 trials · 8 indications
| Arm | Type | Description |
|---|---|---|
| A | PLACEBO_COMPARATOR | - |
| B | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| NC-503 (eprodisate disodium) | DRUG | capsules of 400 mg Dosage: 4 capsules (1600 mg) BID for 26 weeks |
| placebo | OTHER | Dosage: 4 capsules BID for 26 weeks |
| NC-503 (Anti-amyloidotic (AA) Agent) | DRUG | - |
Inclusion Criteria: * Age and gender eligibility: 30 years and older * Diagnosis of Type 2 diabetes mellitus * Patients treated with a stable therapeutic dose of either metformin, a sulfonylurea agent, or metformin in combination with a sulfonylurea agent for a minimum period of 3 months prior to t...
NC-503 is an investigational small molecule developed by GSK plc for metabolic disease. It has been studied in Type 2 diabetes mellitus and metabolic syndrome. Development reached Phase 2, and the compound is also known as eprodisate disodium. It is not an approved therapy and remains a clinical-stage research asset.
NC-503 was studied as a treatment for Type 2 diabetes mellitus and metabolic syndrome. The Phase 2a proof-of-concept trial enrolled adults aged 30 years and older with Type 2 diabetes. The program is investigational, so NC-503 is not an approved treatment for Type 2 diabetes or any other condition.
NC-503 is developed by GSK plc, which trades under the ticker GSK. GSK sponsored the Phase 2a proof-of-concept study of NC-503 in patients with Type 2 diabetes. The asset is also referred to as eprodisate disodium.
NC-503 reached Phase 2 clinical development. One Phase 2a proof-of-concept trial in Type 2 diabetes has been completed, and no trials are currently active. NC-503 is investigational and has not been approved by the FDA for any indication.
NC-503 has been evaluated in one completed Phase 2a trial, NCT00675857, titled a Phase IIa proof-of-concept study of NC-503 in patients with Type II diabetes. The randomized, double-blind, placebo-controlled study enrolled 200 participants in Canada and included patients with Type 2 diabetes and metabolic syndrome.
Yes, NC-503 is also known as eprodisate disodium. Both names refer to the same investigational small molecule developed by GSK plc for metabolic indications, including Type 2 diabetes mellitus. Searches for either name point to the same Phase 2 clinical program.